PETCT Imaging Using 18F-Fluoroestradiol to Evaluate Estrogen Receptors in Breast Cancer Patients

What this Trial Is About

Breast cancer is a common cancer in women, with up to 70% having hormone receptor-positive tumors, mainly estrogen receptor ER positive. This research aims to evaluate the use of 18F-Fluoroestradiol 18F-FES, a special imaging tracer that targets estrogen receptors, to measure ER expression in primary and metastatic breast cancer. The study focuses on understanding ER levels to better guide treatment decisions, especially since ER status can vary between original and metastatic tumors. The study uses 18F-FES PETCT imaging, which specifically detects estrogen receptor-positive tumors with high accuracy. This imaging method may help predict how patients respond to endocrine therapy and assist in selecting patients who may benefit more from hormone treatment versus chemotherapy. Patients undergo PETCT scans that visualize ER expression in their breast cancer tumors. Participants will have their ER status assessed by 18F-FES PETCT imaging. Researchers will measure the maximum standardized uptake value SUVmax over a five-year period as the main outcome. The study involves consenting adults diagnosed with breast cancer and excludes pregnant women and those with severe conditions that prevent PET examination. This observational study helps improve understanding of breast cancer characteristics and treatment planning.

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer